<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999124</url>
  </required_header>
  <id_info>
    <org_study_id>NaDiA-01</org_study_id>
    <nct_id>NCT04999124</nct_id>
  </id_info>
  <brief_title>Characteristics of NAFLD Among Type 2 Diabetes Patients</brief_title>
  <official_title>Study of the Characteristics of Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus Patients Followed in a Hospital Environment in Flanders, Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during&#xD;
      previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was&#xD;
      found. The investigators want to determine the characteristics of this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VCTEM (KPa) measure</measure>
    <time_frame>up to year four</time_frame>
    <description>The FibroScan® device measures vibration controlled transient elastography (VCTE) (kPa) Based on these values the liver stiffness status will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAPTM (dB/m) measure</measure>
    <time_frame>up to year four</time_frame>
    <description>The FibroScan® device measures controlled attenuation parameter (CAP) (dB/m) Based on these values the liver steatosis status will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Ultrasound</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF (Electronic Patient file) the results of a possible earlier ultrasound are noted in the CRF. The results are noted as 'liver steatosis found' with yes/no answer and the year in which this ultrasound was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver biopsy</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the results of a possible earlier ultrasound or liver biopsy are noted in the CRF. The results are noted as previous NAFLD diagnosis with yes/no answer and if confirmed by liver biopsy results. Next the NAS CRN (histological) score is noted.The score ranges from 0-8 and is composed of the unweighted sum of steatosis, ballooning, and lobular inflammation. A score between 0-2 corresponds to no NASH, 3-4 is borderline NASH, and definite NASH has a score between 5 and 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate transaminase (AST)</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter AST (U/L) will be collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine transaminase (ALT)</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter ALT (U/L) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gamma glutamyltransferase (GGT)</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter GGT (U/L) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate dehydrogenase (LDH)</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter LDH (U/L) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total protein</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter total protein (g/L) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter albumin (mg/dL) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ferritin</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter ferritin (µg/L) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bilirubin total</measure>
    <time_frame>up to year four</time_frame>
    <description>Out of the EPF the blood parameter bilirubin total (mg/dL) will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exclusion of other liver diseases</measure>
    <time_frame>up to year four</time_frame>
    <description>hepatitis B, hepatitis C, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, Wilson disease and alpha 1 antitrypsin deficiency. NAFLD is a disease of exclusion and therefore the abovementioned parameters are determined out of the EPF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>up to year four</time_frame>
    <description>The weight (kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>up to year four</time_frame>
    <description>The height (m)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI (Body Mass Index)</measure>
    <time_frame>up to year four</time_frame>
    <description>The weight (kg) and height (m) will be determined and from this the BMI (kg/m²) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>waist circumference</measure>
    <time_frame>up to year four</time_frame>
    <description>The waist circumference will be measured and noted in cm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wellbeing - BAECKE</measure>
    <time_frame>up to year four</time_frame>
    <description>This questionnaire will be used to estimate the level of physical activity. It exists out of 16 questions about work, sports and leisure time. A higher score means that the person is more active at work, does more sport and has a more active leisure time. Minimum value is 3 and maximum value is 15.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wellbeing - GAD-7</measure>
    <time_frame>up to year four</time_frame>
    <description>General Anxiety Disorder (GAD-7) questionnaire will be used to determine the presence of possible clinically significant anxiety disorder.A higher scores indicates having anxiety. Minimum score is 0 and maximum score is 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wellbeing - PHQ-9</measure>
    <time_frame>up to year four</time_frame>
    <description>Patient Health Questionnaire-9 (PHQ-9) will be used to quantify depression symptoms and monitor severity. . Minimum score is 0 and maximum score is 27. A higher score indicates having a depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wellbeing - WPAI-SHP</measure>
    <time_frame>up to year four</time_frame>
    <description>Workers Productivity and Activity Impairment (WPAI-SHP) questionnaire. By means of 6 questions about work productivity and activity it can be determined if there is absence, productivity loss or a decrease in activities at work. By means of 6 questions about work productivity and activity it can be determined if there is absence, productivity loss or a decrease in activities at work. The score is expressed in percentages (0-100). A higher percentage indicates a higher absence from work and a lower productivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wellbeing - SF-36</measure>
    <time_frame>up to year four</time_frame>
    <description>Short Form Health Survey-36 will be used to determine the health related quality of life based on 6 different topics: physical functioning, social functioning, role restrictions, mental wellbeing, energy and pain. The score is expressed in percentages (0-100). A higher percentage indicates a better general wellbeing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis Diabetes</measure>
    <time_frame>up to year four</time_frame>
    <description>The year of diagnosis is asked to the patient (yr).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes complications</measure>
    <time_frame>up to year four</time_frame>
    <description>The complications (retinopathy, nephropathy and neuropathy) of diabetes are asked to the patient and gathered out of the EPF. Answer will be yes/no to each of the complications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concomitant medication</measure>
    <time_frame>up to year four</time_frame>
    <description>The medication use will be noted in the CRF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatine</measure>
    <time_frame>up to year four</time_frame>
    <description>serum creatine (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine creatine</measure>
    <time_frame>up to year four</time_frame>
    <description>urine creatine (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micro-albumin</measure>
    <time_frame>up to year four</time_frame>
    <description>micro-albumin (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin/creatine ratio</measure>
    <time_frame>up to year four</time_frame>
    <description>albumin/creatine ratio (mg/g creat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate</measure>
    <time_frame>up to year four</time_frame>
    <description>estimated glomerular filtration rate (ml/min/1,73m²).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (mg/dL)</measure>
    <time_frame>up to year four</time_frame>
    <description>Triglycerides (mg/dL) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL (mg/dL)</measure>
    <time_frame>up to year four</time_frame>
    <description>HDL (mg/dL) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol (mg/dL)</measure>
    <time_frame>up to year four</time_frame>
    <description>LDL cholesterol (mg/dL) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol (mg/dL).</measure>
    <time_frame>up to year four</time_frame>
    <description>Total cholesterol (mg/dL) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombocytes</measure>
    <time_frame>up to year four</time_frame>
    <description>thrombocytes (1000/µL) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose (mg/dL)</measure>
    <time_frame>up to year four</time_frame>
    <description>fasting glucose (mg/dL) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial alpha fetoprotein (AFP)</measure>
    <time_frame>up to year four</time_frame>
    <description>partial alpha fetoprotein (AFP) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>haemoglobin A1c (%)</measure>
    <time_frame>up to year four</time_frame>
    <description>haemoglobin A1c (%) in blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes Mellitus patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening and studying characteristics</intervention_name>
    <description>Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. Now we want to determine the characteristics of this population.</description>
    <arm_group_label>Type 2 Diabetes Mellitus patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years,&#xD;
&#xD;
          -  having type 2 diabetes,&#xD;
&#xD;
          -  able to understand Dutch,&#xD;
&#xD;
          -  able to understand the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  excessive alcohol abuse,&#xD;
&#xD;
          -  other liver disease,&#xD;
&#xD;
          -  secondary causes of steatosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leen Heyens, drs.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <phone>+32 89 32 65 05</phone>
    <email>geert.robaeys@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leen Heyens, drs.</last_name>
    <phone>+32 89 21 20 55</phone>
    <email>leen.heyens@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leen Heyens, drs.</last_name>
      <phone>+32 21 20 55</phone>
      <email>leen.heyens@uhasselt.be</email>
    </contact>
    <investigator>
      <last_name>Geert Robaeys, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Geert Robaeys</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>NAFLD, characteristics</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>hospital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

